press releases

Dr. Ben Chien, CEOs of QPS and Foresee Pharma, Named an EY Entrepreneur Of The Year® 2016 Finalist for Greater Philadelphia

Nomination a by-product of employee, client, vendor and community support

Dr. Benjamin Chien, CEO of QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, has been named a finalist for the prestigious EY Entrepreneur Of The Year® 2016 Award in Greater Philadelphia.

For 30 years, this award program has recognized entrepreneurs demonstrating excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Today, the EY Entrepreneur Of The Year® Awards program operates in over 145 cities in more than 60 countries worldwide. Dr. Chien was selected by a panel of ten dedicated, independent judges including past winners and area civic and community leaders. To view other finalists, click here.

This year’s Greater Philadelphia finalists will attend a gala on June 9th at the Terrace Ballroom, Pennsylvania Convention Center, where the winner will be announced. Regional EY Entrepreneur Of The Year® Award winners will then be eligible for several national awards as well as the overall national award. These winners will be announced at the EY Entrepreneur Of The Year National Awards gala in Palm Springs, California in November. Past recipients include entrepreneurs such as Howard Schultz of Starbucks Coffee Company, John Mackey of Whole Foods Market Inc., Pierre Omidyar of eBay, Inc., Reid Hoffman and Jeff Weiner of LinkedIn Corporation and Mindy Grossman of HSN, Inc.

Dr. Chien founded Quest Pharmaceutical Services (QPS) in 1995 as a single-site CRO focused on bioanalysis. Today QPS employs over 1150 people in the United States, Europe, India and Asia. Additionally, its research division was spun out in 2011 as Foresee Pharmaceuticals, Co., Ltd. It became publicly listed in Taiwan emerging stock market in early 2016. “Our company’s success is the result of hard-working employees, trusted vendors, loyal clients, supportive investors and great community support,” said Dr. Chien. “We are both honored and excited to be recognized by the EY Entrepreneur Of The Year® Award judging panel, especially from such an impressive field of nominees.”

EY Entrepreneur Of The Year® is the only competitive awards program in the world for entrepreneurs and leaders of high-growth companies. The US overall award winner will go on to compete for the EY World Entrepreneur Of The Year™ Award in Monaco in June, 2017.

Media Contacts:

QPS
Reinier Schwietert
Vice President of Global Marketing
+31 (50) 304 8003
reinier.schwietert@qps.com

Foresee Pharmaceuticals
Patricia Chou
Chief Financial Officer
+886 (2) 2655-2658
patricia.chou@foreseepharma.com

About QPS Holdings, LLC
Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) and life sciences products supplier supporting discovery, preclinical, and clinical drug development, providing quality services to pharmaceutical and biotechnology clients worldwide. QPS linearly integrated core competencies include: neuropharmacology, DMPK, liver research, toxicology, bioanalysis, translational medicine, and early and late phase clinical research program management. QPS regional laboratories and testing facilities are located at company headquarters in Newark, DE; Springfield, MO; Fargo, ND; Research Triangle Park, NC; Hollywood, FL; South Miami, FL, USA; Groningen, The Netherlands; Graz, Austria; Hyderabad, India; Barcelona, Spain; and Taipei, Taiwan.

For more information, visit: http://www.qps.com

About Foresee Pharmaceuticals, Co., Ltd.
Foresee Pharmaceuticals Co., Ltd. (FP) is a clinical-stage pharmaceutical company. Our mission is to serve patients. We strive to improve patients' quality of life and provide cure through innovative research. We are committed to apply the highest ethical standards to our products, services and communications. Foresee's core competency includes rapid development and commercialization of new drugs using its proprietary drug delivery technology as well as develop first-in-class NCE in disease areas of high unmet medical needs.

For more information, visit: http://www.foreseepharma.com

About EY
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.

For more information about our organization, please visit: http://www.ey.com

 

Download
back
top
20 years in pharma R&D navigation